Clinical Trials Logo

Malignant Melanoma, Metastatic clinical trials

View clinical trials related to Malignant Melanoma, Metastatic.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03715985 Active, not recruiting - Clinical trials for Non Small Cell Lung Cancer Metastatic

Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac)

NeoPepVac
Start date: January 28, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objective is to assess tolerability and safety of a personalized neo-antigen vaccine containing up to 15 peptides derived from somatic mutation of the individual patient's cancer, with CAF09b as adjuvant. The vaccine formulation will be administered in combination with an approved anti-PD-1 or anti-PD-L1 inhibitor to patients with advanced solid tumors. The endpoint is the characterization of adverse events (AE) assessed by CTCAE 4.0. The secondary objective is feasibility to manufacture a personalized neo-antigen vaccine within 6 weeks of enrolment with the PIONEER pipeline, and to evaluate the immune response before, during and after treatment with the personalized neo-antigen vaccine. And evaluate the effect on the immune response correlated to dose escalation of peptides in the vaccine. The endpoint is to evaluate the induction of adaptive immune responses to the personalized neo-antigen vaccine measured by functional assays and peptide-MHC multimer stainings. The tertiary objective is to evaluate the clinical efficacy of the treatment. The endpoints will be objective responses (OR), progression free survival (PFS) and overall survival (OS).